Hong Kong · Delayed Price · Currency is HKD Clover Biopharmaceuticals Statistics
Total Valuation
HKG:2197 has a market cap or net worth of HKD 2.48 billion. The enterprise value is 2.37 billion.
| Market Cap | 2.48B |
| Enterprise Value | 2.37B |
Important Dates
The next estimated earnings date is Wednesday, November 25, 2026.
| Earnings Date | Nov 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:2197 has 1.30 billion shares outstanding. The number of shares has increased by 1.58% in one year.
| Current Share Class | 1.30B |
| Shares Outstanding | 1.30B |
| Shares Change (YoY) | +1.58% |
| Shares Change (QoQ) | +2.42% |
| Owned by Insiders (%) | 20.60% |
| Owned by Institutions (%) | 9.30% |
| Float | 796.41M |
Valuation Ratios
The trailing PE ratio is 2.48.
| PE Ratio | 2.48 |
| Forward PE | n/a |
| PS Ratio | 4,995.68 |
| PB Ratio | -2.68 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 2.41 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.73
| Current Ratio | 0.73 |
| Quick Ratio | 0.57 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,502.53 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -44.48% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -476.30% |
| Weighted Average Cost of Capital (WACC) | 18.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 257 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.75 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.60% in the last 52 weeks. The beta is 2.57, so HKG:2197's price volatility has been higher than the market average.
| Beta (5Y) | 2.57 |
| 52-Week Price Change | +1.60% |
| 50-Day Moving Average | 1.98 |
| 200-Day Moving Average | 2.28 |
| Relative Strength Index (RSI) | 40.79 |
| Average Volume (20 Days) | 3,849,234 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HKG:2197 had revenue of HKD 496,423 and earned 982.63 million in profits. Earnings per share was 0.77.
| Revenue | 496,423 |
| Gross Profit | -6.39M |
| Operating Income | -343.46M |
| Pretax Income | 982.63M |
| Net Income | 982.63M |
| EBITDA | -325.17M |
| EBIT | -343.46M |
| Earnings Per Share (EPS) | 0.77 |
Balance Sheet
The company has 117.23 million in cash and 2.41 million in debt, with a net cash position of 114.83 million or 0.09 per share.
| Cash & Cash Equivalents | 117.23M |
| Total Debt | 2.41M |
| Net Cash | 114.83M |
| Net Cash Per Share | 0.09 |
| Equity (Book Value) | -924.97M |
| Book Value Per Share | -0.73 |
| Working Capital | -55.63M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 18.52M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -69,186.53% |
| Pretax Margin | 197,942.84% |
| Profit Margin | 197,942.79% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HKG:2197 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.58% |
| Shareholder Yield | -1.58% |
| Earnings Yield | 39.62% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |